|
業務類別
|
Biotechnology |
|
業務概覽
|
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics. |
| 公司地址
| 9704 Medical Center Drive, Rockville, MD, USA, 20850 |
| 電話號碼
| +1 301 251-5172 |
| 傳真號碼
| +1 301 251-5321 |
| 公司網頁
| https://www.macrogenics.com |
| 員工數量
| 293 |
| Ms. Beth Smith |
Vice President, Controller and Treasurer |
-- |
08/04/2026 |
| Dr. Ezio Bonvini, M.D. |
Senior Vice President, Research and Chief Scientific Officer |
美元 533.20K |
08/04/2026 |
| Mr. James Karrels |
Senior Vice President, Chief Financial Officer and Principal Accounting Officer |
美元 506.55K |
08/04/2026 |
| Mr. Eric Risser |
Director, President and Chief Executive Officer |
美元 561.57K |
08/04/2026 |
| Dr. Thomas Spitznagel, PhD |
Senior Vice President, Technical Operations |
-- |
08/04/2026 |
| Mr. Jeffrey Stuart Peters |
Senior Vice President, General Counsel, Corporate Secretary and Corporate Compliance Officer |
-- |
08/04/2026 |
|
|
| Dr. David C. Stump,M.D. |
Independent Director |
08/04/2026 |
| Dr. Scott Koenig, M.D.,PhD |
Director |
08/04/2026 |
| Mr. William K. Heiden |
Chairman of the Board |
08/04/2026 |
| Ms. Meenu Chhabra Karson |
Independent Director |
08/04/2026 |
| Dr. Margaret A. Liu, M.D. |
Independent Director |
08/04/2026 |
| Mr. Edward M. Hurwitz, J.D. |
Independent Director |
08/04/2026 |
| Mr. Scott T. Jackson, M.B.A. |
Independent Director |
08/04/2026 |
| Mr. Eric Risser |
Director, President and Chief Executive Officer |
08/04/2026 |
| Dr. Karen Jean Ferrante, M.D. |
Independent Director |
08/04/2026 |
| Dr. Jay Siegel, M.D. |
Independent Director |
08/04/2026 |
| Ms. Federica O'Brien |
Independent Director |
08/04/2026 |
|
|
|
|
